Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

<p>NORSE EIGHT study on track to commence in Q1 2024 Resubmission of ONS-5010 Biologics License Application (BLA) in the U.S. expected by the end of calendar year 2024 ISELIN, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/outlook-therapeutics-submits-special-protocol-assessment-spa-to-fda-for-non-inferiority-study-of-ons-5010/">Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>